Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18FET PET for Difficult Clinical Situations in Functional Pituitary Adenoma
NCT07360548Phase 2Not yet recruiting
- Sponsor
- CHU de Lille
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of O-(2-[18F]fluoroethyl)-L-tyrosine in pituitary adenoma, sponsored by CHU de Lille. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
O-(2-[18F]fluoroethyl)-L-tyrosine
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on NCT07360548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360548.